Home › Funds › Acasta Partners UK LLP › ARWR
Acasta Partners UK LLP position in ARWR
ARROWHEAD PHARMACEUTICALS IN · Health Care
Acasta Partners UK LLP reported holding 1,500,000 shares of ARWR (ARROWHEAD PHARMACEUTICALS IN) in its Q3 2026 13F filing — a position valued at US$1.5M, representing 0.81% of its reported portfolio and ranking #11 among its reported holdings. Acasta Partners UK LLP has disclosed ARWR holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
Last updated: 2026-10-09 · Source: SEC EDGAR Form 13F-HR
How Acasta Partners UK LLP's ARWR position evolved
Acasta Partners UK LLP first disclosed a stake in ARWR in Q1 2026 at 400,000 shares (US$415K). The position peaked in Q2 2026 at 1,500,000 shares, worth US$1.8M. Across 3 filings, Acasta Partners UK LLP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 1,500,000 shares valued at US$1.5M. Notable position changes include a 275% increase in Q2 2026 (shares fell 20% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 400.00K | $414.63K | New |
| Q2 2026 | 1.50M | $1.81M | Add |
| Q3 2026 | 1.50M | $1.54M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ARWR and 13F data
ARWR (ARROWHEAD PHARMACEUTICALS IN) is a Health Care company. 53 other funds we track also report a position in ARWR — the largest reported positions include Avoro Capital Advisors LLC (US$925.6M), FRED ALGER MANAGEMENT, LLC (US$269.1M), BAKER BROS. ADVISORS LP (US$162.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ARWR
- Avoro Capital Advisors LLC 11.36M sh · $925.59M · Q2 2026
- FRED ALGER MANAGEMENT, LLC 3.30M sh · $269.14M · Q2 2026
- BAKER BROS. ADVISORS LP 1.99M sh · $162.43M · Q2 2026
- Siren, L.L.C. 1.72M sh · $139.83M · Q2 2026
- Vestal Point Capital, LP 1.57M sh · $128.38M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 1.39M sh · $113.22M · Q2 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 1.35M sh · $110.08M · Q2 2026
- Hood River Capital Management LLC 1.12M sh · $91.35M · Q2 2026
- SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC 830.25K sh · $67.67M · Q2 2026
- Western Financial Corp/CA 820.24K sh · $53.68M · Q3 2026
- READYSTATE ASSET MANAGEMENT LP 25.00M sh · $29.94M · Q2 2026
- MACKAY SHIELDS LLC 27.19M sh · $27.84M · Q3 2026
More on Acasta Partners UK LLP
FAQ
How long has Acasta Partners UK LLP held ARWR?
Acasta Partners UK LLP has disclosed ARWR holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is Acasta Partners UK LLP's current position in ARWR?
As of Q3 2026, Acasta Partners UK LLP holds 1.50M shares of ARWR (ARROWHEAD PHARMACEUTICALS IN), valued at $1.54M, representing 0.81% of its reported portfolio and ranking #11.
Has Acasta Partners UK LLP been buying or selling ARWR?
In the latest 13F filing (Q3 2026), Acasta Partners UK LLP held unchanged its position in ARWR. The position peaked in Q2 2026 at 1.50M shares.
Which other funds hold ARWR?
Other major institutional holders of ARWR include Avoro Capital Advisors LLC, FRED ALGER MANAGEMENT, LLC, BAKER BROS. ADVISORS LP, among 53 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.